Charles Schwab Investment Management Inc Summit Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,485,072 shares of SMMT stock, worth $34.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,485,072
Previous 1,432,713
3.65%
Holding current value
$34.2 Million
Previous $31.4 Million
15.52%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$563 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$269 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$151 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$129 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...